BRCA1 and ovarian neoplasm: As expected, breast and ovarian tumors from BRCA1/2 germline mutation carriers have even higher HR deficiency scores (average value > 50 for BRCA2 and > 60 for BRCA1 mutation carriers) (Fig. 7b and c).